Breaking News Instant updates and real-time market news.

AABA

Altaba

$67.19

-0.94 (-1.38%)

, SFTBF

SoftBank

$0.00

(0.00%)

05:58
10/02/18
10/02
05:58
10/02/18
05:58

Yahoo Japan to shut down GeoCities service in March 2019

Yahoo Japan announced yesterday that it will shut down its GeoCities service in March 2019. Reference Link

AABA

Altaba

$67.19

-0.94 (-1.38%)

SFTBF

SoftBank

$0.00

(0.00%)

AABA Altaba
$67.19

-0.94 (-1.38%)

07/11/18
GABE
07/11/18
DOWNGRADE
GABE
Hold
Altaba downgraded to Hold from Buy at Gabelli
Gabelli analyst Brett Harriss downgraded Altaba to Hold following news the company has entered entered into an agreement with Softbank, to sell up to 614 million shares of Yahoo! Japan for JPY 360 per share, $3.26 per share, or $2 billion in proceeds. The analyst said it is now more likely than not that Altaba liquidates its holdings in fully taxable transactions and lowered his recommendation.
08/15/18
MKMP
08/15/18
NO CHANGE
Target $115
MKMP
Buy
Altaba price target lowered to $115 from $124 at MKM Partners
MKM Partners analyst Rob Sanderson lowered his price target on Altaba (AABA) to $115 to account for the tax liability of its recent divestment of Alibaba (BABA) and Yahoo Japan stakes along with its own stock repurchase. The analyst also keeps his Buy rating on Altaba, stating that the recent volatility in its stock is all macro related, which should be limited to currency transition since the consumption economy in China still has "very strong drivers".
08/24/18
JPMS
08/24/18
INITIATION
Target $88
JPMS
Overweight
Altaba resumed with an Overweight at JPMorgan
JPMorgan analyst Doug Anmuth resumed coverage of Altaba (AABA) with an Overweight rating and lowered his price target for the shares to $88 from $91. The analyst says his longer-term view remains positive with his bull thesis driven by upside potential from Alibaba (BABA) and the stock's attractive risk/reward profile.
09/13/18
JEFF
09/13/18
UPGRADE
JEFF
Buy
Yahoo Japan upgraded to Buy from Hold at Jefferies
Jefferies analyst Hiroko Sato upgraded Yahoo Japan (YAHOY) to Buy and raised his price target for the shares to 500 yen from 400 yen. An overhang has been lifted as Altaba (AABA) exits its stake, Sato tells investors in a research note. Further, he notes that Yahoo Japan is moving forward by adding more services such as PayPay. He's "making a valuation call" saying the stock is at the cheaper end of his e-commerce coverage.
SFTBF SoftBank
$0.00

(0.00%)

05/31/18
05/31/18
UPGRADE
Target $50

Outperform
General Motors upgraded to Outperform after SoftBank investment at Evercore ISI
As previously reported, Evercore ISI analyst George Galliers upgraded General Motors (GM) to Outperform from In Line after SoftBank's (SFTBF) Vision Fund agreed to invest in the company's Cruise autonomous driving unit in a deal that values the unit at $11.5B. Galliers said he had been assigning no value to the Cruise assets before the announcement. Under his new sum-of-the-parts valuation, Galliers applies a 6.0x multiple on GM's core, attributes a value of about $8 per share for the Cruise assets and about 60c per share for GM's stake in Lyft before applying a 25% discount to both of the latter. He raised his price target on GM shares to $50 from $47.
06/06/18
MSCO
06/06/18
NO CHANGE
MSCO
Morgan Stanley says Softbank stake in Cruise significant 'far beyond' just GM
Morgan Stanley analyst Adam Jonas said Softbank's (SFTBF) recently announced investment in GM Cruise "carries significance far beyond" General Motors (GM), arguing that the increasingly conspicuous involvement of "outside validators" such as large-cap tech firms and prominent investors can accelerate perception change in the capital markets about "Auto 2.0." He envisions the possible formation of two different companies currently held under one automaker's roof, which he dubs an Auto 2.0 "Yieldco" and an Auto 2.0 "Growthco." Converting car owners into monthly subscribers could open up significant revenue, profit, and value opportunities for traditional automakers, argues Jonas in a note to investors. Other automaking "OEMs" include Ford (F), Daimler (DDAIF), Toyota (TM), Honda (HMC), Fiat Chrysler (FCAU) and BMW Group (BAMXY).
07/10/18
RBCM
07/10/18
NO CHANGE
Target $53
RBCM
Outperform
General Motors price target raised to $53 at RBC Capital
RBC Capital analyst Joseph Spak kept his Outperform rating on General Motors (GM) and nudged his price target to $53 from $52, saying the recent $2.25B investment by Softbank (SFTBF) adds validation to the company's GM Cruise robo-taxi offering plans. Aside from the validation, Spak notes that the investment "provides capital to reach scale commercialization, affords GM capital allocation flexibility, and unlocks GM share price value as Cruise around $7 per share."
09/07/18
OPCO
09/07/18
NO CHANGE
Target $275
OPCO
Outperform
Palo Alto Networks price target raised to $275 from $235 at Oppenheimer
Oppenheimer analyst Shaul Eyal maintained an Outperform rating on Palo Alto Networks (PANW) and raised his price target to $275 from $235 following the company's "robust" Q4 results, noting that the results "beat almost every possible metric." In a research note to investors, Eyal says that the CEO transition appears to be progressing smoothly and he "appreciated" constructive conference call commentary from CEO Nikesh Arora about his strategic vision, even though he is only 90 days into the new role. Eyal contends that Palo Alto Networks remains a "builder rather than a buyer," and that Arora's former experience -- at Google (GOOGL) and SoftBank (SFTBF) -- should not be interpreted as a sign of "future splashy acquisitions."

TODAY'S FREE FLY STORIES

BX

Blackstone

$34.66

-0.61 (-1.73%)

17:00
10/21/18
10/21
17:00
10/21/18
17:00
Periodicals
Blackstone to acquire Ulterra for $700M, Reuters reports »

Blackstone has agreed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

, KKR

KKR

$24.22

-0.45 (-1.82%)

16:56
10/21/18
10/21
16:56
10/21/18
16:56
Periodicals
Fiat agrees to sell Magneti Marelli to KKR's Calsonic, Bloomberg says »

Fiat Chrysler (FCAU) has…

FCAU

Fiat Chrysler

$15.52

0.035 (0.23%)

KKR

KKR

$24.22

-0.45 (-1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 30

    Oct

MRK

Merck

$72.34

0.12 (0.17%)

, AZN

AstraZeneca

$39.21

0.25 (0.64%)

16:40
10/21/18
10/21
16:40
10/21/18
16:40
Hot Stocks
Merck, AstraZeneca announce detailed results from Phase 3 SOLO-1 trial »

AstraZeneca (AZN) and…

MRK

Merck

$72.34

0.12 (0.17%)

AZN

AstraZeneca

$39.21

0.25 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 11

    Jan

  • 16

    Feb

VAR

Varian Medical

$104.25

-1.575 (-1.49%)

16:31
10/21/18
10/21
16:31
10/21/18
16:31
Hot Stocks
Varian unveils new Bravos afterloader system for brachytherapy treatments »

Varian announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

14:30
10/21/18
10/21
14:30
10/21/18
14:30
Conference/Events
Neon Therapeutics management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 07

    Nov

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13
Hot Stocks
G1 presents additional data from randomized Phase 2 trial in first-line SCLC »

G1 Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09
Hot Stocks
NuCana reports additional data on NUC-1031 in advanced biliary tract cancer »

NuCana announced combined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

, MRK

Merck

$72.34

0.12 (0.17%)

14:05
10/21/18
10/21
14:05
10/21/18
14:05
Hot Stocks
Leap Therapeutics presents esophagogastric cancer data »

Leap Therapeutics (LPTX)…

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

INCY

Incyte

$66.09

1.66 (2.58%)

14:02
10/21/18
10/21
14:02
10/21/18
14:02
Hot Stocks
Incyte announces positive interim data from Phase 2 trial of Pemigatinib »

Incyte announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58
Hot Stocks
Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer »

Bayer (BAYRY) and Loxo…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53
Hot Stocks
Loxo announces larotrectinib clinical update in patients with TRK fusion cancers »

Loxo Oncology (LOXO)…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45
Hot Stocks
Mirati announces updated data from ongoing trial of single agent sitravatinib »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39
Hot Stocks
Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34
Hot Stocks
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib »

Gilead Sciences (GILD)…

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

, MRK

Merck

$72.34

0.12 (0.17%)

13:27
10/21/18
10/21
13:27
10/21/18
13:27
Hot Stocks
BioLineRx discloses additional data from Phase 2a COMBAT/KEYNOTE-202 study »

BioLineRx (BLRX)…

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

ADAP

Adaptimmune

$10.79

-0.09 (-0.83%)

13:22
10/21/18
10/21
13:22
10/21/18
13:22
Hot Stocks
Adaptimmune presents updated data from ongoing MAGE-A10, MAGE-A4 studies »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02
Hot Stocks
Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56
Hot Stocks
Pfizer presents overall survival data from PALOMA-3 trial of Ibrance »

Pfizer announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:52
10/21/18
10/21
12:52
10/21/18
12:52
Hot Stocks
Merck presents early data for STING agonist in advanced solid tumors/lymphomas »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47
Hot Stocks
Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma »

Dynavax (DVAX) presented…

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

12:44
10/21/18
10/21
12:44
10/21/18
12:44
Hot Stocks
Exelixis announces results from data analysis of CABOSUN, METEOR trials »

Exelixis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 14

    Jan

AGEN

Agenus

$1.97

-0.025 (-1.26%)

12:39
10/21/18
10/21
12:39
10/21/18
12:39
Hot Stocks
Agenus presents clinical data on PD-1, CTLA-4 at ESMO 2018 »

Agenus presented updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

OMED

OncoMed

$2.47

-0.17 (-6.44%)

12:37
10/21/18
10/21
12:37
10/21/18
12:37
Hot Stocks
OncoMed announces interim phase 1b results for Navicixizumab, Paclitaxel combo »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:34
10/21/18
10/21
12:34
10/21/18
12:34
Hot Stocks
ImmunoGen presents initial data from FORWARD II expansion cohort »

ImmunoGen (IMGN)…

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 02

    Nov

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30
Hot Stocks
Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.